ACCESS Newswire

Eviva Partners, a New Nonprofit Promoting Better Understanding of Medical Evidence, Exposes Role of Andrew Wakefield in the “Manufacture of Evidence” Leading Up to Robert F. Kennedy Jr’s Confirmation Hearings

10.2.2025 07:50:00 CET | ACCESS Newswire | Press release

Share

Introduces the concept of "Evidence Fluency" as a solution to the current crisis and a path towards improving healthcare overall

NEW YORK CITY, NEW YORK / ACCESS Newswire / February 10, 2025 / Eviva Partners, a pioneering healthcare initiative founded by physician-scientist Alex Morozov, announced its launch today with an innovative mission to address critical gaps in healthcare delivery through "evidence fluency" - a new framework for understanding and communicating medical evidence.

"The new US Administration is poised to have a dramatic impact on the integrity of scientific publications and medical evidence," said Alex Morozov, CEO and Founder. "An investigation over the past several days reveals a role of Andrew Wakefield in the "Manufacture of Evidence" leading up to Robert F. Kennedy Jr's Confirmation hearings. Wakefield 30 years ago was paid by another anti-vaccine lawyer, Richard Barr, to manufacture a study through research fraud showing a link between vaccines and autism. History now repeats itself, except now the anti-vaccine lawyer, Kennedy, could become in charge of US science and medicine as a whole."

Eviva Partners's solution to this crisis is simple: "Evidence Fluency." The premise is that one key, previously overlooked factor underlies the current challenges of poor and unequal outcomes and rising costs in the U.S. healthcare system: insufficient "evidence fluency" among patients, providers, and other healthcare stakeholders.

"We are a nonpartisan organization committed to helping improve health outcomes for all" said Morozov.

Eviva Partners introduces the concept of "evidence fluency" as a solution to the current crisis and a path towards improving healthcare overall, defined as having four components:

  • Understanding the concept of evidence as distinct from "proof;"

  • Ability to assess the strength of evidence;

  • Ability to detect manipulation;

  • Ability to discuss evidence with others.

Eviva Partners will focus on three areas:

  1. Pioneering deep characterization of care gaps (both underuse and overuse), starting in hematology-oncology care, at the state level;

  2. Developing a multi-pronged approach to increase evidence fluency through:

    • "Two-Eyed Seeing" methodology for bridging worldviews

    • K-12 evidence curriculum

    • A tool kit for patients and providers

  3. Creating state and federal policy proposals to improve healthcare transparency and quality, starting with protecting the integrity of scientific literature.

The organization has assembled a distinguished advisory council including Elder Albert Marshall of the Mi'kmaw Nation, creator of the "Two-Eyed Seeing" methodology; Stephan Lewandowsky, a leading cognitive scientist at the University of Bristol, and others.

"Our preliminary surveys show that only 16% of U.S. adults correctly understand the difference between evidence and proof, while 36% have never heard the word 'evidence' used in a medical context," said Morozov. "By improving evidence fluency across the healthcare ecosystem, we can help close care gaps and ultimately improve health outcomes for all."

Initial pilot studies will focus on sickle cell disease and cancer, where care gaps are high. In addition, K-12 evidence curriculum will be piloted. Once those are completed, the organization plans to launch a nationwide public awareness campaign to promote evidence fluency.

For more information about Eviva Partners, and to read Alex Morozov's expose, "Robert F. Kennedy Jr, Andrew Wakefield and The Manufacture of Evidence," visit www.evivapartners.org, or follow Eviva Partners on Twitter, BlueSky, LinkedIn, Facebook and Instagram.

Contact Information

Alex Morozov
CEO and Founder
alex.morozov@evivapartners.org
9173751112

SOURCE: Eviva Partners



View the original press release on ACCESS Newswire

Eviva Partners

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Fermi Announces New Agreements with Investment-Grade Hyperscaler and Third Quarter 2026 Financial Results12.11.2026 13:00:00 CET | Press release

DALLAS, TX / ACCESS Newswire / November 12, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), today announced its third quarter 2026 financial results and multiple new agreements with an investment-grade hyperscaler to advance 600 megawatts ("MW") of power capacity at Project Matador. A conference call is scheduled for 9 a.m. Eastern Time / 2 p.m. British Time today, November 12, 2026. Accompanying slides and prepared remarks can be found at https://investor.fermiamerica.com. Participation details are included in this release. "Hyperscalers want sites that are ready with permitted power, and Fermi's Project Matador is one of few that can meet that demand today," said Lee McIntire, Fermi Chief Executive Officer. "Our headstart in speed to power is a key reason an investment-grade hyperscaler has signed up for 600 megawatts and committed more than $200 million up front to accelerate construction at Project Matador with an additional $90 mi

Nexteer Announces First Share Repurchase Programme of Up to US$60 Million12.11.2026 01:40:00 CET | Press release

HONG KONG, HK / ACCESS Newswire / November 11, 2026 / Nexteer Automotive today announced that its Board of Directors has approved, the Company's first share repurchase programme of up to US$60 million, equivalent to approximately HK$471 million. The programme reflects the Board's confidence in Nexteer's business and long-term prospects. The Group's strong liquidity position supports returning capital to shareholders while continuing to invest in the business and its future development. Disciplined Capital Allocation The programme complements Nexteer's dividend distributions and represents a further step in returning capital to shareholders. It follows the dividend paid out in July 2026 of approximately US$46 million, representing 45% of the Company's net income attributable to shareholders for the year ending December 31, 2025 -and the highest dividend payout ratio in the Company's history. Nexteer remains committed to disciplined capital allocation, balancing investment in the busines

GoodData.AI Launches the Agentic Serving Plane, a New Category of Enterprise Data Infrastructure for AI Agents10.11.2026 15:30:00 CET | Press release

SAN FRANCISCO, CA / ACCESS Newswire / November 10, 2026 / GoodData.AI, the open agentic analytics platform, today launched the Agentic Serving Plane, a governed execution layer designed for the high-concurrency, context-rich data workloads created by AI agents. The Agentic Serving Plane sits between enterprise data platforms and the applications, analytics experiences and agents that consume them. It provides workload serving, business semantics, contextual grounding, access control, and AI execution services through a common governed layer. The current enterprise data infrastructure was designed primarily for humans: occasional queries, predictable workloads, and access by known users. AI agents operate differently. A single business task can generate tens or hundreds of short-lived data operations as an agent investigates, reasons, and decides what to ask next. When many agents operate simultaneously, intermittent human querying becomes continuous, high-concurrency agentic demand. Ag

Envision Pharma Group appoints Leigh Anne Siino as Senior Vice President of Commercial, Two Labs and Riparian10.11.2026 15:00:00 CET | Press release

FAIRFIELD, CT / ACCESS Newswire / November 10, 2026 / Envision Pharma Group (Envision), a global, technology-enabled solutions partner to the life sciences industry, has appointed Leigh Anne Siino as Senior Vice President of Commercial, Two Labs and Riparian. Siino will lead a team providing best-in-class launch and revenue management services to the biopharma community. Pharma and biotech companies across the industry seek suppliers who can support them from their earliest stages, often before they have built in-house commercial, market access, and revenue management capabilities. Two Labs provides commercialization services and consulting support as these companies prepare for and execute successful launches; Riparian offers consulting, managed services, and technology to manage and protect revenue as their therapies reach patients. Together, Envision's Two Labs and Riparian businesses offer a single, connected solution spanning launch and beyond. Under Siino's leadership, clients wi

Securitas Healthcare Introduces a New Era of RTLS Built for the Future of Healthcare Operations10.11.2026 14:00:00 CET | Press release

LINCOLN, NE / ACCESS Newswire / November 10, 2026 / Securitas Healthcare, a leading provider of real-time visibility and protection solutions for the healthcare industry, today announced the next generation of its MobileView® Real-Time Location System (RTLS) platform. The expanded platform introduces MobileView Cloud, new solution capabilities, enhanced user experiences, and flexible deployment, technology, and integration options that help healthcare organizations transform real-time visibility into operational intelligence. As health systems navigate workforce shortages, capacity constraints, and growing demands for efficiency and better patient experiences, timely access to operational and clinical information has become essential to managing increasingly complex care environments. Today's RTLS platforms provide the visibility and intelligence needed to improve patient throughput, enhance safety, optimize resource utilization, and support the connected operations required to enable

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye